Elevated expression of PLTP is atherogenic in apolipoprotein E deficient mice

Atherosclerosis

Volumn 227, Issue 1, 2013, Pages 37-42

  Van Haperen, Rien ^a   Van Gent, Teus ^a   Van Tol, Arie ^a   De Crom, Rini ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Lipoproteins; PLTP

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; DIET, HIGH-FAT; HUMANS; MALE; MICE; MICE, INBRED C57BL; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 84873448968     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.11.022     Document Type: Article

References (30)

1. Albers J.J., Vuletic S., Cheung M.C. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim Biophys Acta 2011, 1821:345-357.
2. Masson D., Jiang X.C., Lagrost L., Tall A.R. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 2009, 50:S201-S206.
3. Jiang X.C., Bruce C., Mar J., et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999, 103:907-914.
4. Jiang X.C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001, 7:847-852.
5. Colhoun H.M., Taskinen M.R., Otvos J.D., Van Den Berg P., O'Connor J., Van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002, 51:3300-3305.
6. De Vries R., Dallinga-Thie G.M., Smit A.J., Wolffenbuttel B.H., van Tol A., Dullaart R.P. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
7. Riemens S., van Tol A., Sluiter W., Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998, 140:71-79.
8. Van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002, 13:135-139.
9. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003, 23:1857-1862.
10. Schlitt A., Blankenberg S., Bickel C., et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009, 50:723-729.
11. Vergeer M., Boekholdt S.M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
12. Van Haperen R., Van Tol A., Van Gent T., et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002, 277:48938-48943.
13. Van Haperen R., Samyn H., Moerland M., et al. Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One 2008, 3:e2255.
14. Linton M.F., Atkinson J.B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995, 267:1034-1037.
15. Mahley R.W., Rail S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
16. Zanotti I., Pedrelli M., Poti F., et al. Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2011, 31:74-80.
17. Kockx M., Jessup W., Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol 2008, 28:1060-1067.
18. Linton M.F., Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Curr Opin Lipidol 1999, 10:97-105.
19. Hasty A.H., Linton M.F., Swift L.L., Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J Lipid Res 1999, 40:1529-1538.
20. Van Eck M., Herijgers N., Yates J., et al. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:3117-3126.
21. Jiang X., Francone O.L., Bruce C., et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996, 98:2373-2380.
22. Yang X.P., Yan D., Qiao C., et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003, 23:1601-1607.
23. Yazdanyar A., Jiang X.C. Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice. Hepatology 2012, 56:576-584.
24. Valenta D.T., Ogier N., Bradshaw G., et al. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol 2006, 26:1572-1578.
25. Vikstedt R., Ye D., Metso J., et al. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol 2007, 27:578-586.
26. Masson D., Deckert V., Gautier T., et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. Arterioscler Thromb Vasc Biol 2011, 31:766-774.
27. Quintao E.C., Cazita P.M. Lipid transfer proteins: past, present and perspectives. Atherosclerosis 2010, 209:1-9.
28. Jarvik G.P., Rajagopalan R., Rosenthal E.A., et al. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res 2010, 51:983-990.
29. Lagor W.R., Rader D.J. Phospholipidation of HDL-how much is too much?. Clin Chem 2011, 57:4-6.
30. Luo Y., Shelly L., Sand T., et al. Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. J Pharmacol Exp Ther 2010, 332:1100-1106.